acute promyelocytic leukemia
Conditions
Interventions
APL patients who present white blood cell count >
3,000 on admission, will receive high-dose of cytarabine plus intrathecal injection in addition to conventional chemotherapy plus ATRA therapy at the consolidation chemotherapy.
APL patients who prese
3,000 on admission, will receive conventional chemotherapy combined with ATRA therapy.
Sponsors
Fukuoka Blood & Marrow Transplant Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Acute promyelocytic leukemia by WHO classification 2. The first time treatment example which does not catch chemotherapy or the radiotherapy 3. The case that is equal to or less than 65 years old more than age 15 years old 4. Performance status 0-2 5. A case without the dangerously ill internal organs disorder; T.Bil equal to or less than 2.0mg/dL, Cr equal to or less than 2.0mg/dL 6. The case that an agreement by the document is provided from a patient on explanation because of final examination contents
Exclusion criteria
Exclusion criteria: 1. The case having double cancers 2. The case with an infectious disease having difficulty with control 3. The case with a severe mental disorder 4. The pregnancy or breast-feeding woman 5. The case that the medical attendant judged to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 years disease-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 5 years disease free survival, CR rate, treatment-related toxicities | — |
Countries
Japan
Contacts
Public ContactToshihiro Miyamoto
Kyushu University Hospital Hematology/ Oncology
Outcome results
None listed